comparemela.com
Home
Live Updates
AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma : comparemela.com
AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma
TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of...
Related Keywords
Japan ,
Spain ,
Liechtenstein ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Norway ,
Iceland ,
Institut Catal ,
Genmab Duobody ,
Roopal Thakkar ,
Anna Sureda ,
Us Inc ,
Macrophage Propertiesj Immunol ,
Exchange Commission ,
Facebook ,
Youtube ,
Development Of Novel Anti ,
Drug Administration ,
European Commission ,
Twitter ,
European Union ,
Administration Of Tepkinly ,
European Medicines Agency ,
Instagram ,
Linkedin ,
Important Safety Information ,
Lysis Syndrome ,
Product Characteristics ,
Release Syndrome ,
Full Prescribing Information ,
Medication Guide ,
Allergan Aesthetics ,
Private Securities Litigation Reform Act ,
Quarterly Reports ,
Largeb Cell Lymphoma ,
Conditional Marketing ,
Accessed August ,
Clinically Utilized ,
Directed Antibodies ,
Macrophage Properties ,
Novel Anti Cd ,
Cell Surface ,
Cancer Sci ,
Markets ,
comparemela.com © 2020. All Rights Reserved.